Subscribe to Search results

Professor Savidge described UKHCDO in the 1970s and 1980s as an isolated and autonomous advisory body without formal affiliation with the NHS, any Royal College or learned society (eg: British Society on Haematology) with its own self appointed working parties.

Published on:

Professor Savidge stated "extra money when found was spent on the purchase of commercial imported factor VIII concentrate, usually from the US, in preference to the safer cryoprecipitate that was the recommend [sic] treatment of children and mild haemophilia patients (assuming failure with DDAVP) generally available (in some regions in excess).

Published on:

St Thomas' Hospital's annual return for 1976 showed that cryoprecipitate and NHS Factor 8 were the most used products.

Published on:

St Thomas' Hospital's annual return for 1977 recorded that cryoprecipitate and NHS Factor 8 were the most used products.

Published on:

St Thomas' Hospital's annual return for 1978 recorded higher commercial concentrate use than NHS Factor 8.

Published on:

St Thomas' Hospital's annual return for 1978 shows recorded that over a million units of commercial Factor 8 were used that year.

Published on:

Professor Edward Tuddenham was co-director of the Royal Free Hospital.

Published on:

Royal Free Hospital began to use commercial concentrate.

Published on:

Royal Free's annual return recorded that Haemophilia A patients were treated primarily with cryoprecipitate, followed by commercial concentrates, then NHS Factor 8.

Published on:

Royal Free's annual return shows 2,102,310 units of cryoprecipitate, 601,681 units of commercial concentrates and 510,200 units of NHS Factor 8.

Published on:

Dr Katharine Dormandy wrote to Dr Richard Lane, describing the Royal Free's treatment policy "to use NHS-concentrate for patients on home treatment and for those who are allergic to cryoprecipitate."

Published on:

Dr Katharine Dormandy initiated home treatment with cryoprecipitate at the Royal Free.

Published on:

Drs Kernoff and Tuddenham became co-directors of the Royal Free and moved patients from cryoprecipitate to concentrate.

Published on:

Royal Free began to measure the ratio of T4 and T8 cells in patients with haemophilia.

Published on:

The policy of deferring the elective surgery commenced, as recalled by Professor Christine Lee.

Published on:

Dr Dormandy pioneered home therapy with cryoprecipitate, as recalled by Professor Christine Lee.

Published on:

Royal Free had a policy of keeping patients on the same batch until it ran out, as recalled by Professor Christine Lee.

Published on:

Professor Lee, expressed the firm view that the Royal Free's haemophilia centre directors could not be criticised for the complete change from cryoprecipitate to concentrate, also citing the convenience and the efficiency as reasons for change.

Published on:

Royal Free used, for the first time, more units of commercial concentrates than cryoprecipitate over the course of 1978.

Published on:

The volume of commercial concentrates used at the Royal Free in 1979 was double that of NHS Factor 8 and cryoprecipitate.

Published on: